Ovid Therapeutics (OVID) Equity Average (2017 - 2026)

Ovid Therapeutics has reported Equity Average for 10 years, with the latest figure at $164.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 157.98% year-over-year to $164.5 million; the trailing twelve-month figure through Mar 2026 stood at $164.5 million (up 157.98% YoY), and the FY2025 full-year result was $99.4 million, up 27.47% from the prior year.
• Equity Average for Q1 2026 stood at $164.5 million, up from $87.7 million in the prior quarter.
• The five-year high for Equity Average was $172.4 million in Q1 2022, with the low at $50.2 million in Q3 2025.
• Historically, Equity Average has averaged $106.1 million across 5 years, with a median of $94.5 million in 2023.
• Annual changes were most pronounced in 2025 — Equity Average sank 39.17% — and 2026, when it surged 157.98%.
• Ovid Therapeutics' Equity Average stood at $137.2 million in 2022, then tumbled by 31.07% to $94.5 million in 2023, then dropped by 23.57% to $72.3 million in 2024, then advanced by 21.34% to $87.7 million in 2025, then surged by 87.58% to $164.5 million in 2026.
• The last three Equity Average figures came in at $164.5 million (Q1 2026), $87.7 million (Q4 2025), and $50.2 million (Q3 2025), per Business Quant data.